Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
1.
Br J Radiol ; 88(1053): 20150163, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26133222

RESUMEN

OBJECTIVE: To investigate the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DWI) in monitoring early therapeutic response to sorafenib in renal cell carcinoma (RCC) xenograft models. METHODS: Sorafenib (40 mg kg(-1)) was administered orally to BALB/c nude mice (n = 9) bearing subcutaneous tumours of human RCC ACHN xenografts. DCE-MRI and DWI were obtained 0, 1, 3 and 7 days after therapy, and DCE-MRI parameters (K(trans) and ve) and apparent diffusion coefficient (ADC) values were calculated. Tumour size and volume changes were correlated with changes in DCE-MRI parameters or ADC values after therapy. RESULTS: Following therapy, K(trans) showed a significant decrease over time (p = 0.005), whereas ve did not demonstrate significant changes between time points (p = 0.97). ADC values showed a progressive increase over time (p = 0.004). Compared with pre-therapy, K(trans) showed a significant decrease after 3 days of therapy (p = 0.039), and ADC values increased significantly after 7 days (p = 0.039). Tumour size and volume did not show significant changes during 7 days. Tumour size and volume changes were not associated with changes in DCE-MRI parameters or ADC values. CONCLUSION: DCE-MRI and DWI may show early physiological changes within 1 week after initiating sorafenib treatment on human RCC xenografts. ADVANCES IN KNOWLEDGE: The quantitative parameters of DCE-MRI and DWI may offer the potential for assessing early therapeutic response to sorafenib in clinical trials.


Asunto(s)
Carcinoma de Células Renales/tratamiento farmacológico , Neoplasias Renales/tratamiento farmacológico , Imagen por Resonancia Magnética/métodos , Niacinamida/análogos & derivados , Compuestos de Fenilurea/uso terapéutico , Inhibidores de Proteínas Quinasas/uso terapéutico , Animales , Biomarcadores de Tumor/metabolismo , Medios de Contraste , Imagen de Difusión por Resonancia Magnética/métodos , Modelos Animales de Enfermedad , Estudios de Factibilidad , Masculino , Ratones , Ratones Desnudos , Niacinamida/uso terapéutico , Pronóstico , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Sorafenib , Resultado del Tratamiento
2.
Asian J Androl ; 15(4): 503-7, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23708462

RESUMEN

Several reports have promoted the root-derived Korean red ginseng (KRG; Panax ginseng) as alternative treatment for erectile dysfunction (ED), and ginsenosides are known to be the principal active ingredients of ginseng. Recent studies showed that ginseng berries produce more ginsenosides than KRG; thus, we investigated the ability of the Korean ginseng berry extract GB0710 to relax the penile corpus cavernosum smooth muscle (CCSM) in this study. As a comparative control, the results were compared to those obtained using KRG. In addition, possible mechanisms of action for GB0710 were investigated. While KRG and GB0710 both displayed dose-dependent relaxation effects on precontracted rabbit CCSM in vitro, GB0710 was shown to be more potent than KRG. The GB0710-induced relaxation could be partially reduced by removing the endothelium. In addition, pre-treatment with several nitric oxide (NO) inhibitors significantly inhibited the relaxation of muscle strips. Furthermore, administration of GB0710 increased intracavernosal pressure (ICP) in a rat in vivo model in both a dose- and duration-dependent manner. Intracellular NO production in human microvascular endothelial cells could be induced by GB0710 and inhibited by N(G)-monomethyl-L-arginine. In conclusion, GB0710 had a greater relaxation effect on rabbit CCSM than did KRG extract, and increased ICP in a rat model in both a dose- and a duration-dependent manner. This relaxing effect might be mediated by NO production.


Asunto(s)
Células Endoteliales/efectos de los fármacos , Frutas , Panax/química , Erección Peniana/efectos de los fármacos , Extractos Vegetales/farmacología , Animales , Relación Dosis-Respuesta a Droga , Células Endoteliales/citología , Inhibidores Enzimáticos/farmacología , Células Endoteliales de la Vena Umbilical Humana , Humanos , Técnicas In Vitro , Masculino , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Óxido Nítrico/metabolismo , Erección Peniana/fisiología , Raíces de Plantas/química , Conejos , Ratas , Ratas Sprague-Dawley , República de Corea , omega-N-Metilarginina/farmacología
3.
Amino Acids ; 43(1): 5-12, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22327512

RESUMEN

The main determinant of muscle carnosine (M-Carn) content is undoubtedly species, with, for example, aerobically trained female vegetarian athletes [with circa 13 mmol/kg dry muscle (dm)] having just 1/10th of that found in trained thoroughbred horses. Muscle fibre type is another key determinant, as type II fibres have a higher M-Carn or muscle histidine containing dipeptide (M-HCD) content than type I fibres. In vegetarians, M-Carn is limited by hepatic synthesis of ß-alanine, whereas in omnivores this is augmented by the hydrolysis of dietary supplied HCD's resulting in muscle levels two or more times higher. ß-alanine supplementation will increase M-Carn. The same increase in M-Carn occurs with administration of an equal molar quantity of carnosine as an alternative source of ß-alanine. Following the cessation of supplementation, M-Carn returns to pre-supplementation levels, with an estimated t1/2 of 5-9 weeks. Higher than normal M-Carn contents have been noted in some chronically weight-trained subjects, but it is unclear if this is due to the training per se, or secondary to changes in muscle fibre composition, an increase in ß-alanine intake or even anabolic steroid use. There is no measureable loss of M-Carn with acute exercise, although exercise-induced muscle damage may result in raised plasma concentrations in equines. Animal studies indicate effects of gender and age, but human studies lack sufficient control of the effects of diet and changes in muscle fibre composition.


Asunto(s)
Carnosina/metabolismo , Ejercicio Físico/fisiología , Fibras Musculares Esqueléticas/metabolismo , Músculo Esquelético/metabolismo , Carnosina/sangre , Dieta Vegetariana , Femenino , Humanos , Masculino , Músculo Esquelético/química , Caracteres Sexuales , beta-Alanina
4.
Amino Acids ; 32(2): 225-33, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16868650

RESUMEN

Muscle carnosine synthesis is limited by the availability of beta-alanine. Thirteen male subjects were supplemented with beta-alanine (CarnoSyn) for 4 wks, 8 of these for 10 wks. A biopsy of the vastus lateralis was obtained from 6 of the 8 at 0, 4 and 10 wks. Subjects undertook a cycle capacity test to determine total work done (TWD) at 110% (CCT(110%)) of their maximum power (Wmax). Twelve matched subjects received a placebo. Eleven of these completed the CCT(110%) at 0 and 4 wks, and 8, 10 wks. Muscle biopsies were obtained from 5 of the 8 and one additional subject. Muscle carnosine was significantly increased by +58.8% and +80.1% after 4 and 10 wks beta-alanine supplementation. Carnosine, initially 1.71 times higher in type IIa fibres, increased equally in both type I and IIa fibres. No increase was seen in control subjects. Taurine was unchanged by 10 wks of supplementation. 4 wks beta-alanine supplementation resulted in a significant increase in TWD (+13.0%); with a further +3.2% increase at 10 wks. TWD was unchanged at 4 and 10 wks in the control subjects. The increase in TWD with supplementation followed the increase in muscle carnosine.


Asunto(s)
Carnosina/biosíntesis , Suplementos Dietéticos , Músculo Esquelético/metabolismo , beta-Alanina/administración & dosificación , beta-Alanina/farmacología , Adulto , Biopsia , Carnosina/metabolismo , Esquema de Medicación , Prueba de Esfuerzo , Humanos , Concentración de Iones de Hidrógeno , Masculino , Modelos Biológicos , Músculo Esquelético/efectos de los fármacos , Protones , Taurina/metabolismo , Factores de Tiempo
5.
Plant Cell Rep ; 23(10-11): 692-8, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15480686

RESUMEN

We describe a procedure for producing transgenic bottle gourd plants by inoculating cotyledon explants with Agrobacterium tumefaciens strain AGL1 that carries the binary vector pCAMBIA3301 containing a glufosinate ammonium-resistance (bar) gene and the beta-D-glucuronidase (GUS) reporter gene. The most effective bacterial infection was observed when cotyledon explants of 4-day-old seedlings were co-cultivated with Agrobacterium for 6-8 days on co-cultivation medium supplemented with 0.1-0.001 mg/l L-alpha-(2-aminoethoxyvinyl) glycine (AVG). The putatively transformed shoots directly emerged at the proximal end of cotyledon explants after 2-3 weeks of culturing on selection medium containing 2 mg/l DL-phosphinothricin. These shoots were rooted after 3 weeks of culturing on half-strength MS medium containing 0.1 mg/l indole acetic acid and 1 mg/l DL-phosphinothricin. Transgenic plants were obtained at frequencies of 1.9%. Stable integration and transmission of the transgenes in T1 generation plants were confirmed by a histochemical GUS assay, polymerase chain reaction and Southern blot analyses. Genetic segregation analysis of T1 progenies showed that transgenes were inherited in a Mendelian fashion. To our knowledge, this study is the first to show Agrobacterium-mediated transformation in bottle gourd.


Asunto(s)
Agrobacterium tumefaciens/genética , Cucurbitaceae/genética , Glicina/análogos & derivados , Transformación Genética , Aminobutiratos/farmacología , Southern Blotting , Cucurbitaceae/efectos de los fármacos , Cucurbitaceae/microbiología , Etilenos/farmacología , Glucuronidasa/genética , Glicina/farmacología , Brotes de la Planta , Plantas Modificadas Genéticamente , Reacción en Cadena de la Polimerasa , Regeneración
6.
Eur J Cancer Prev ; 12(5): 383-90, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14512803

RESUMEN

We investigated clinical efficacy of green tea extracts (polyphenon E; poly E and (-)-epigallocatechin-3-gallate [EGCG]) delivered in a form of ointment or capsule in patients with human papilloma virus (HPV) infected cervical lesions. Fifty-one patients with cervical lesions (chronic cervicitis, mild dysplasia, moderate dysplasia and severe dysplasia) were divided into four groups, as compared with 39 untreated patients as a control. Poly E ointment was applied locally to 27 patients twice a week. For oral delivery, a 200 mg of poly E or EGCG capsule was taken orally every day for eight to 12 weeks. In the study, 20 out of 27 patients (74%) under poly E ointment therapy showed a response. Six out of eight patients under poly E ointment plus poly E capsule therapy (75%) showed a response, and three out of six patients (50%) under poly E capsule therapy showed a response. Six out of 10 patients (60%) under EGCG capsule therapy showed a response. Overall, a 69% response rate (35/51) was noted for treatment with green tea extracts, as compared with a 10% response rate (4/39) in untreated controls (P<0.05). Thus, the data collected here demonstrated that green tea extracts in a form of ointment and capsule are effective for treating cervical lesions, suggesting that green tea extracts can be a potential therapy regimen for patients with HPV infected cervical lesions.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Catequina/análogos & derivados , Catequina/farmacología , Papillomaviridae/patogenicidad , Infecciones por Papillomavirus/complicaciones , Té/química , Displasia del Cuello del Útero/tratamiento farmacológico , Neoplasias del Cuello Uterino/prevención & control , Cervicitis Uterina/tratamiento farmacológico , Administración Oral , Administración Tópica , Adulto , Antineoplásicos Fitogénicos/administración & dosificación , Catequina/administración & dosificación , Femenino , Humanos , Activador de Plasminógeno de Tipo Uroquinasa/antagonistas & inhibidores , Displasia del Cuello del Útero/virología , Cervicitis Uterina/virología
7.
Leukemia ; 17(7): 1375-83, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12835727

RESUMEN

The aim of this study was to evaluate the potential of tumor-necrosis-factor-related apoptosis-inducing ligand TRAIL to eradicate leukemia cell lines, while sparing normal hematopoietic stem cells. Human Jurkat and Molt-4 cell lines were used to optimize the purging process in umbilical cord blood (UCB) mononuclear cells. The Jurkat cell line was TRAIL sensitive and TRAIL-resistant Molt-4 cell line became sensitive after being treated with TRAIL and a low dose of doxorubicin (0.1 micro M), but UCB mononuclear cells remained resistant. DR4 expression was increased when Jurkat cells were treated with TRAIL, and DR5 expression increased after exposing Molt-4 cells to TRAIL plus a low dose of doxorubicin for 24 h. The expression of DR4 and DR5 in UCB mononuclear cells was unchanged after treatment with TRAIL, a low-dose doxorubicin, or TRAIL plus a low dose of doxorubicin. In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Experiments involving mixture of UCB mononuclear cells and Jurkat or Molt-4 cells showed a marked eradication of leukemia cells and the limiting dilution assay demonstrated an eradication rate of more than 4 logs after 24 h incubation with 100 ng/ml of TRAIL in Jurkat cells. In the case of Molt-4 cells, the eradication rate was about 3 logs when TRAIL was used in combination with a low dose of doxorubicin. No significant decrease in the number of granulocyte-macrophage colony-forming unit) (CFU-GM) colonies was detected when UCB mononuclear cells were treated with TRAIL in combination with a low dose of doxorubicin. These results suggest that TRAIL offers the possibility of being used as an ex vivo purging agent for autologous transplantation in hematologic malignancies.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/métodos , Leucemia/patología , Glicoproteínas de Membrana/farmacología , Factor de Necrosis Tumoral alfa/farmacología , Proteínas Reguladoras de la Apoptosis , Caspasas/efectos de los fármacos , Caspasas/metabolismo , Doxorrubicina/farmacología , Evaluación Preclínica de Medicamentos , Sangre Fetal/efectos de los fármacos , Trasplante de Células Madre Hematopoyéticas/normas , Humanos , Glicoproteínas de Membrana/uso terapéutico , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF , Receptores del Factor de Necrosis Tumoral/análisis , Ligando Inductor de Apoptosis Relacionado con TNF , Trasplante Autólogo , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/uso terapéutico
8.
Endocrinology ; 141(6): 2244-53, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10830314

RESUMEN

We tested the hypothesis that nitric oxide and carbon monoxide, which are produced in the brain by nitric oxide synthase (NOS) and heme oxygenase (HO), modulate the hypothalamic-pituitary-adrenal response to physico-emotional stressors by acting at the hypothalamus. Accordingly, we determined 1) whether the intracerebroventricular (icv) injection of NOS or HO inhibitors at doses that were confined to the brain attenuated electroshock-induced ACTH release; and 2) whether the decreases in this ACTH response were concurrent with decreases in NOS or HO activity levels at the hypothalamus. Icv injection of the NOS inhibitor Nomega-nitro-L-arginine-methylester (L-NAME; 50 microg) or the HO inhibitor tin protoporphyrin (SnPP; 20-25 microg) significantly blunted the plasma ACTH response to a 45-min session of intermittent electroshocks. Importantly, in these same animals there were concurrent decreases in hypothalamic NOS or HO activities, respectively. There were little or no effects of these inhibitors on anterior pituitary NOS or HO activities, indicating that there was only minimal leakage of the drug from the brain after icv administration. The specificity of action of these inhibitors was confirmed by the fact that SnPP did not affect NOS activity, and L-NAME did not affect HO activity. Finally, L-NAME produced no effect, whereas SnPP produced only transient increases in blood pressure, suggesting that these inhibitors do not affect activity indirectly through alterations in blood pressure. These data support the hypothesis that in the whole animal, both NO and CO exert a stimulatory influence on the acute ACTH response to physico-emotional stressors, and that the hypothalamus is the critical site of their actions.


Asunto(s)
Glándulas Suprarrenales/fisiología , Monóxido de Carbono/fisiología , Hipotálamo/fisiología , Óxido Nítrico/fisiología , Adenohipófisis/fisiología , Estrés Fisiológico , Glándulas Suprarrenales/efectos de los fármacos , Hormona Adrenocorticotrópica/sangre , Animales , Presión Sanguínea/efectos de los fármacos , Electrochoque , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacología , Hemo Oxigenasa (Desciclizante)/antagonistas & inhibidores , Hemo Oxigenasa (Desciclizante)/metabolismo , Hipotálamo/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Metaloporfirinas/farmacología , NG-Nitroarginina Metil Éster/administración & dosificación , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/metabolismo , Adenohipófisis/efectos de los fármacos , Protoporfirinas/farmacología , Ratas , Ratas Sprague-Dawley
9.
J Microencapsul ; 17(3): 297-306, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10819418

RESUMEN

To compare cationic liposomes (CatL) and neutral liposomes (NeuL), as a vaccine carrier, the in vivo fate and immunogenicity of hepatitis B surface antigen (HBsAg), incorporated in CatL and NeuL, were investigated. CatL, composed of phosphatidyl choline (PC) and stearyl amine (SA) with a molar ratio of 9:1, showed a 2.5-fold higher incorporating efficiency of HBsAg than NeuL composed of PC alone. Most of HBsAg incorporated in both liposomes existed in an antibody-available form on the outer surface of liposomes. After intramuscular injection to rats, HBsAg in CatL resided at the injection site for a longer period than that in NeuL with terminal half lives of 52.5 and 42.9 h, respectively. However, HBsAg in NeuL was more efficiently taken up by the lymphatic organs and spleen than that in CatL. Furthermore, the group treated with HBsAg in NeuL showed earlier sero-conversion with higher anti-HBsAg titre than the group treated with HBsAg in CatL. Sero-conversion rates (SCRs) in both CatL- and NeuL-treated animals were 100% after every injection carried out, except the primary injection of CatL. These results demonstrate that CatL can enhance the retention of incorporated antigen at the injection site, compared with NeuL. However, the production of antibody by HBsAg in NeuL is more effective than that by HBsAg in CatL, probably due to the higher lymphatic targeting ability of NeuL. Thus, NeuL appears to be a better carrier for HBsAg than CatL.


Asunto(s)
Antígenos de Superficie de la Hepatitis B/administración & dosificación , Antígenos de Superficie de la Hepatitis B/inmunología , Adyuvantes Inmunológicos , Animales , Formación de Anticuerpos/inmunología , Área Bajo la Curva , Cationes , Portadores de Fármacos , Hipersensibilidad Tardía/inmunología , Inyecciones Intramusculares , Radioisótopos de Yodo , Liposomas , Masculino , Ratas , Ratas Wistar
10.
Arch Pharm Res ; 23(1): 66-71, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10728660

RESUMEN

Peonjahwan, an oriental traditional medicine composed of crude herbal drugs and animal tissues is bitter and poorly water-soluble. To mask the bitterness of peonjahwan and enhance the release of bilirubin, one of the crude active ingredients of peonjahwan, peonja dry elixir (PDE), was prepared using a spray-dryer after extracting the crude materials in ethanol-water solution. Coated peonja dry elixir (CPDE) was then prepared by coating the PDE with Eudragit acrylic resin. Panel assessed bitterness and release test of bilirubin from PDE and CPDE were carried out and compared with peonjahwan alone. PDE was found to have little effect upon the reduction of the bitterness of peonjahwan. However, the bitterness of CPDE was found to reduce to 1/4 of that of peonjahwan due to the encapsulation of crude active ingredients by the dextrin and Eudragit shell (P<0.05). The release rate of bilirubin from PDE and CPDE for 60 min increased about 3.5- and 2.5- fold, respectively, compared to peonjahwan at pH 1.2. It is concluded that CPDE, which masked the bitterness of peonjahwan and enhanced the release of bilirubin, is a preferable delivery system for peonjahwan.


Asunto(s)
Sistemas de Liberación de Medicamentos , Medicina Tradicional de Asia Oriental , Bilirrubina/metabolismo , Formas de Dosificación , Etanol/administración & dosificación , Gusto
11.
J Nat Prod ; 63(12): 1702-4, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11141123

RESUMEN

The present study was performed to evaluate the effect of steaming ginseng at a temperature over 100 degrees C on its chemical constituents and biological activities. Raw ginseng was steamed at 100, 110, and 120 degrees C for 2 h using an autoclave. The ginseng steamed at 120 degrees C was more potent in its ability to induce endothelium-dependent relaxation. Steaming the raw ginseng at 120 degrees C also remarkably increased the radical-scavenging activity. Ginsenosides F(4), Rg(3), and Rg(5), which were not present in raw ginseng, were produced after steaming. Ginsenosides Rg(3) and Rg(5) were the most abundant ginsenosides in the ginseng steamed at 120 degrees C, accounting for 39% and 19% of all ginsenosides, respectively.


Asunto(s)
Panax , Plantas Medicinales , Saponinas/farmacología , Cromatografía Líquida de Alta Presión , Ginsenósidos , Calor , Estructura Molecular , Saponinas/química , Saponinas/aislamiento & purificación , Análisis Espectral
12.
J Neurosci ; 19(17): 7640-7, 1999 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-10460269

RESUMEN

We investigated the effect of the intracerebroventricular injection of the nitric oxide (NO) donor 3-morpholino-sydnonimine (SIN-1) on the release of adrenocorticotropin hormone (ACTH) and the neuronal response of hypothalamic neurons responsible for this release. Rats that were administered SIN-1 showed significant elevations in plasma ACTH levels, a response that was virtually abolished by antibodies against corticotropin-releasing factor (CRF) and significantly blunted by vasopressin (VP) antiserum. SIN-1 also upregulated heteronuclear (hn) transcripts for CRF and VP and messenger RNA (mRNA) levels for the immediate early gene NGFI-B and for CRF receptor type 1 (CRF-R(1)) in the parvocellular portion of the paraventricular nucleus (PVN) of the hypothalamus. Blockade of prostaglandin synthesis with ibuprofen did not alter the ACTH or the PVN response to SIN-1. The central nucleus of the amygdala and the supraoptic nucleus, regions that are involved in autonomic adjustments to altered cardiovascular activity, also responded to SIN-1 with elevated NGFI-B mRNA levels. However, the only change in mean arterial blood pressure caused by this NO donor was a transient and modest increase. To our knowledge, this is the first demonstration that in the intact rat NO stimulates the activity of PVN neurons that control the hypothalamic-pituitary-adrenal axis. It must be noted, however, that our results do not allow us to determine whether this effect was direct or mediated through PVN afferents. This study should help resolve the controversy generated by the use of isolated brain tissues to investigate the net effect of NO on hypothalamic peptide production.


Asunto(s)
Hormona Adrenocorticotrópica/metabolismo , Hormona Liberadora de Corticotropina/genética , Proteínas de Unión al ADN/genética , Regulación de la Expresión Génica/fisiología , Hipotálamo/fisiología , Molsidomina/análogos & derivados , Donantes de Óxido Nítrico/farmacología , Óxido Nítrico/fisiología , Núcleo Hipotalámico Paraventricular/fisiología , Receptores de Hormona Liberadora de Corticotropina/genética , Factores de Transcripción/genética , Transcripción Genética/fisiología , Vasopresinas/genética , Amígdala del Cerebelo/efectos de los fármacos , Amígdala del Cerebelo/fisiología , Animales , Ventrículos Cerebrales/efectos de los fármacos , Ventrículos Cerebrales/fisiología , Regulación de la Expresión Génica/efectos de los fármacos , Genes Inmediatos-Precoces/efectos de los fármacos , Hipotálamo/efectos de los fármacos , Ibuprofeno/farmacología , Inyecciones Intraventriculares , Masculino , Molsidomina/administración & dosificación , Molsidomina/farmacología , Donantes de Óxido Nítrico/administración & dosificación , Miembro 1 del Grupo A de la Subfamilia 4 de Receptores Nucleares , Especificidad de Órganos , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , ARN Mensajero/genética , Ratas , Ratas Sprague-Dawley , Receptores Citoplasmáticos y Nucleares , Receptores de Esteroides/genética , Núcleo Supraóptico/efectos de los fármacos , Núcleo Supraóptico/fisiología , Transcripción Genética/efectos de los fármacos
13.
J Periodontol ; 69(9): 982-8, 1998 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9776026

RESUMEN

This controlled, split-mouth, preclinical study was designed to evaluate outcome following surgical implantation of an allogeneic, freeze-dried demineralized bone matrix-calcium sulfate (DBM+CS) composite with a CS barrier in 3-wall intrabony periodontal defects in 4 dogs. Control conditions included surgical implantation of DBM or CS and gingival flap surgery (GFS) alone. Three-wall intrabony defects (4x4x4 mm) were surgically created at the mesial and distal aspect of the maxillary and mandibular first and third premolars, respectively. Maxillary and mandibular defects each received 1 of the 4 experimental conditions. Experimental conditions were rotated between defect sites in subsequent animals. Block sections of the defects were collected at sacrifice 8 weeks postsurgery and processed for histometric analysis. Histometric defect height (means +/- SD) for the DBM+CS, DBM, CS, and GFS groups amounted to 4.2 +/- 0.5, 4.3 +/- 0.7, 4.0 +/- 0.2, and 4.1 +/- 0.2 mm, respectively. Connective tissue adhesion (connective tissue contact to the root without apparent cementum formation) amounted to 0.4 +/- 0.3, 0.4 +/- 0.3, 0.5 +/- 0.2, and 1.6 +/- 0.5 mm for the DBM+CS, DBM, CS, and GFS groups, respectively; the DBM+CS, DBM, and CS groups being significantly different from the GFS group (P < 0.05). Cementum regeneration amounted to 3.0 +/- 0.3, 3.1 +/- 0.4, 2.5 +/- 0.4, and 1.6 +/- 0.3 mm for the DBM+CS, DBM, CS, and GFS groups, respectively; the DBM+CS, DBM, and CS groups being significantly different from the GFS group (P < 0.05). Alveolar bone regeneration amounted to 2.7 +/- 0.4, 2.7 +/- 0.3, 1.8 +/- 0.5, and 0.7 +/- 0.1 mm for the DBM+CS, DBM, CS, and GFS groups, respectively; the DBM+CS, DBM, and CS groups being different from the GFS group (P < 0.05), and the DBM+CS and DBM groups being different from the CS group (P < 0.05). None of the DBM-containing implants provided evidence of bone metabolic activity. In summary, surgical implantation of DBM and CS, alone or in combination, may result in significantly improved regeneration of alveolar bone and cementum in this preclinical model. Observed regeneration is likely unrelated to a biologic activity inherent in DBM. Rather it appears that space-providing properties of the implants supported observed regeneration.


Asunto(s)
Pérdida de Hueso Alveolar/cirugía , Sustitutos de Huesos/uso terapéutico , Sulfato de Calcio/uso terapéutico , Membranas Artificiales , Periodoncio/fisiopatología , Pérdida de Hueso Alveolar/fisiopatología , Proceso Alveolar/patología , Proceso Alveolar/fisiopatología , Animales , Diente Premolar , Matriz Ósea/trasplante , Regeneración Ósea , Sustitutos de Huesos/química , Sulfato de Calcio/química , Tejido Conectivo/patología , Técnica de Descalcificación , Cemento Dental/patología , Cemento Dental/fisiopatología , Perros , Estudios de Evaluación como Asunto , Liofilización , Gingivoplastia , Mandíbula/cirugía , Maxilar/cirugía , Periodoncio/patología , Regeneración , Propiedades de Superficie , Colgajos Quirúrgicos , Raíz del Diente/patología , Trasplante Homólogo , Resultado del Tratamiento , Cicatrización de Heridas
15.
J Periodontol ; 69(12): 1317-24, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9926761

RESUMEN

THIS RANDOMIZED, CONTROLLED, CLINICAL STUDY was designed to evaluate outcome following surgical implantation of an allogeneic, freeze-dried, demineralized bone matrix-calcium sulfate (DBM+CS) composite with a CS barrier in intrabony periodontal defects. Twenty-six patients contributing 26 deep intrabony defects completed the study. Thirteen patients received the DBM+CS implant. Thirteen patients received gingival flap surgery alone (GFS; control). Clinical outcome was assessed at 6 and 12 months postsurgery. At 12 months postsurgery, probing depth (PD) reduction (mean +/-SD) for the DBM+CS and GFS group was to 4.3+/-0.5 and 3.0+/-1.3 mm; clinical attachment gain was to 2.9+/-0.8 and 1.7+/-1.5 mm; and probing bone level gain was to 2.9+/-1.4 and 1.2+/-1.2 mm, respectively. There were no apparent differences between evaluations at 6 and 12 months postsurgery. Clinical improvements were significantly different from presurgery for both groups at both observation intervals (P < 0.01). There were no significant differences between groups in PD reduction and clinical attachment gain. Probing bone level gain was significantly greater in the DBM+CS group compared to controls (P < 0.05). In summary, surgical implantation of DBM+CS with a CS barrier resulted in reduced PD and improved attachment levels comparable to that achieved by gingival flap surgery alone. However, gain in probing bone levels in deep intrabony periodontal pockets assessed by clinical parameters was greater than that observed by gingival flap surgery alone. These changes were noted at both 6 and 12 months after surgery. This regenerative technique needs further biologic evaluation before being generally accepted.


Asunto(s)
Pérdida de Hueso Alveolar/cirugía , Sustitutos de Huesos/uso terapéutico , Trasplante Óseo/métodos , Sulfato de Calcio/uso terapéutico , Regeneración Tisular Guiada Periodontal/métodos , Membranas Artificiales , Adulto , Pérdida de Hueso Alveolar/patología , Matriz Ósea/trasplante , Femenino , Estudios de Seguimiento , Liofilización , Gingivoplastia , Humanos , Masculino , Persona de Mediana Edad , Pérdida de la Inserción Periodontal/patología , Pérdida de la Inserción Periodontal/cirugía , Bolsa Periodontal/patología , Bolsa Periodontal/cirugía , Colgajos Quirúrgicos , Trasplante Homólogo , Resultado del Tratamiento
16.
Antimicrob Agents Chemother ; 35(1): 158-63, 1991 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-2014971

RESUMEN

Furazolidone and nitrofurantoin, oral nitrofuran derivatives with broad-spectrum antimicrobial properties already in clinical use, were compared for activity against Pneumocystis carinii in an immunosuppressed rat model of P. carinii pneumonia. Furazolidone exhibited only slight activity as a prophylactic agent but was moderately effective in the therapy of pneumocystosis. The median histologic score and organism count fell from 4+ and 10(8) to 10(9) cysts per lung, respectively, in the controls to 1+ to 2+ and 10(7) to 10(8) cysts per lung, respectively, in the furazolidone-treated groups. However, these results were not as good as those obtained with the standard drug, trimethoprim-sulfamethoxazole (0+, 10(6) to 10(7) cysts per lung). Nitrofurantoin showed little anti-P. carinii activity despite different doses or drug preparations. The high doses of furazolidone used here and their toxic effects on the rats will probably discourage investigation of this drug in the treatment of pneumocystosis in humans. Nevertheless, since many nitrofurans have been synthesized, further exploration of this class of compounds might be helpful in developing new anti-P. carinii agents or in studying structure-activity relationships.


Asunto(s)
Furazolidona/uso terapéutico , Nitrofurantoína/uso terapéutico , Neumonía por Pneumocystis/tratamiento farmacológico , Animales , Núcleo Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Furazolidona/efectos adversos , Masculino , Nitrofurantoína/toxicidad , Pneumocystis/efectos de los fármacos , Pneumocystis/ultraestructura , Premedicación , Ratas , Ratas Endogámicas
17.
Ann Ophthalmol ; 17(2): 146-8, 1985 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-3994214

RESUMEN

In recent years there has been much discussion in the literature regarding the proper approach to the patient who presents with apparent "low tension" glaucoma. In addition to a complete workup and proper management of such a patient, careful consideration must be given to the differential diagnosis of clinical conditions presenting with optic disc cupping and visual field changes. We present an interesting clinical situation in which a patient with severe myopia and Leber's optic atrophy was referred for surgery for treatment of apparent progressive "low tension" glaucoma.


Asunto(s)
Glaucoma/diagnóstico , Miopía/diagnóstico , Atrofia Óptica/diagnóstico , Adulto , Diagnóstico Diferencial , Humanos , Masculino , Miopía/complicaciones , Miopía/genética , Atrofia Óptica/complicaciones , Atrofia Óptica/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA